Last reviewed · How we verify
NCT04214496
Electroencephalographic Biomarker to Predict Acute Post-operatory Cognitive Dysfunction
trial testing Sedline in Cognitive Dysfunction in 106 participants. Completed in 4 August 2022.
4 August 2022
Quick facts
| Lead sponsor | University of Chile |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 106 |
| Start date | 4 January 2021 |
| Primary completion | 4 August 2022 |
| Estimated completion | 4 August 2022 |
| Sites | 2 locations across Chile |
Drugs / interventions tested
- Sedline
Conditions studied
- Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
- Postoperative Delirium — all drugs for Postoperative Delirium →
Sponsor
University of Chile
Who can join
60 and older, any sex, with Cognitive Dysfunction or Postoperative Delirium. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute post-operatory cognitive dysfunction states are one of the most important complications in older patients after surgery. Two acute cognitive dysfunctions have been described: postoperative delirium (PD) and postoperative subsyndromal delirium (PSSD). Patients who develop delirium, both as a complete or incomplete syndrome, have poor long-term outcomes, such as longer length of hospital stay, institutionalization at discharge, and even higher mortality, and consequently, the human and economic costs significantly increase for the health system. Here the research team will use an observational cohort, investigator blinded in two-center with a primary endpoint to validate the relative alpha power ratio as a predictive biomarker of postoperative cognitive dysfunctions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04214496
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Dysfunction
Currently open trials in the same condition.
- NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
- NCT07517237 — taVNS + CCT for Neurocognitive Rehab · NA · recruiting
- NCT07171450 — Cognitive Remediation · NA · recruiting
- NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
- NCT07394504 — Effects of Turning Based Dual Task Training on Balance and Mild Cognitive Impairment in Diabetic Peripheral Neuropathy · NA · recruiting
Other University of Chile trials
Trials by the same sponsor.
- NCT07372417 — Macrophage/Monocyte Driven Inflammation and Anesthetic Sensitivity in Aging · not yet recruiting
- NCT07254975 — An Observational Prospective Study of Anesthetic Sensitivity Assessed by Alpha Band Power and Its Association With Emerg · not yet recruiting
- NCT06028854 — Blood Characteristics and Abdominal Emergency Surgery · suspended
- NCT07585669 — Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease · NA · recruiting
- NCT07152171 — Pain Neuroscience Education Delivered During Aerobic Exercise Versus Exercise Alone · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04214496 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chile
- Last refreshed: 7 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04214496.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing